Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Fulvestrant 60Capecitabine 47Trastuzumab 46Letrozole 45pembrolizumab 42Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37abemaciclib 36pertuzumab 34Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Surveys and Questionnaires 26Docetaxel 26Tamoxifen 25Anastrozole 25exemestane 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Omacor × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡